Literature DB >> 12590139

Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation.

Song Hong1, Karsten Gronert, Pallavi R Devchand, Rose-Laure Moussignac, Charles N Serhan.   

Abstract

Docosahexaenoic acid (DHA, C22:6) is highly enriched in brain, synapses, and retina and is a major omega-3 fatty acid. Deficiencies in this essential fatty acid are reportedly associated with neuronal function, cancer, and inflammation. Here, using new lipidomic analyses employing high performance liquid chromatography coupled with a photodiode-array detector and a tandem mass spectrometer, a novel series of endogenous mediators was identified in blood, leukocytes, brain, and glial cells as 17S-hydroxy-containing docosanoids denoted as docosatrienes (the main bioactive member of the series was 10,17S-docosatriene) and 17S series resolvins. These novel mediators were biosynthesized via epoxide-containing intermediates and proved potent (pico- to nanomolar range) regulators of both leukocytes reducing infiltration in vivo and glial cells blocking their cytokine production. These results indicate that DHA is the precursor to potent protective mediators generated via enzymatic oxygenations to novel docosatrienes and 17S series resolvins that each regulate events of interest in inflammation and resolution.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12590139     DOI: 10.1074/jbc.M300218200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  331 in total

1.  Resolving Inflammation: Synthesis, Configurational Assignment, and Biological Evaluations of RvD1n-3 DPA.

Authors:  Jørn Eivind Tungen; Lisa Gerstmann; Anders Vik; Roberta De Matteis; Romain Alexandre Colas; Jesmond Dalli; Nan Chiang; Charles Nicholas Serhan; Markus Kalesse; Trond Vidar Hansen
Journal:  Chemistry       Date:  2018-12-20       Impact factor: 5.236

Review 2.  Paradigm shift in the pharmacological management of periodontal diseases.

Authors:  Hatice Hasturk; Alpdogan Kantarci; Thomas E Van Dyke
Journal:  Front Oral Biol       Date:  2011-11-11

Review 3.  15-Lipoxygenase-1 as a tumor suppressor gene in colon cancer: is the verdict in?

Authors:  Sun Il Lee; Xiangsheng Zuo; Imad Shureiqi
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

4.  Resolvin D1 prevents TNF-α-mediated disruption of salivary epithelial formation.

Authors:  Olutayo Odusanwo; Sreedevi Chinthamani; Andrew McCall; Michael E Duffey; Olga J Baker
Journal:  Am J Physiol Cell Physiol       Date:  2012-01-11       Impact factor: 4.249

Review 5.  Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not?

Authors:  Charles N Serhan
Journal:  Am J Pathol       Date:  2010-09-02       Impact factor: 4.307

6.  Resolvin D1 attenuates activation of sensory transient receptor potential channels leading to multiple anti-nociception.

Authors:  S Bang; S Yoo; T J Yang; H Cho; Y G Kim; S W Hwang
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 7.  Targeting cyclooxygenases-1 and -2 in neuroinflammation: Therapeutic implications.

Authors:  Saba Aïd; Francesca Bosetti
Journal:  Biochimie       Date:  2010-09-22       Impact factor: 4.079

Review 8.  Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins.

Authors:  Matthew Spite; Charles N Serhan
Journal:  Circ Res       Date:  2010-11-12       Impact factor: 17.367

Review 9.  ER stress and effects of DHA as an ER stress inhibitor.

Authors:  Gulnaz Begum; Lloyd Harvey; C Edward Dixon; Dandan Sun
Journal:  Transl Stroke Res       Date:  2013-08-20       Impact factor: 6.829

10.  Biosynthesis of D-Series Resolvins in Skin Provides Insights into their Role in Tissue Repair.

Authors:  Jason Hellmann; Brian E Sansbury; Blenda Wong; Xiaofeng Li; Mansher Singh; Kristo Nuutila; Nan Chiang; Elof Eriksson; Charles N Serhan; Matthew Spite
Journal:  J Invest Dermatol       Date:  2018-03-17       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.